title: Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2a.
abstract: OBJECTIVE
  Increasing evidence suggests the efficacy of maintenance therapy with interferon (IFN) for chronic hepatitis C (CHC) in reducing the risk of hepatocellular carcinoma (HCC). The aim of this study was to determine clinical characteristics on the risk of occurrence of HCC in CHC patients receiving maintenance IFN therapy.
  
  
  METHODS
  A total of 55 patients were treated in a single center with PEG-IFNα-2a monotherapy for CHC and evaluated for variables predictive of the occurrence of HCC.
  
  
  RESULTS
  The cumulative incidences of HCC were 0.092, 0.117 and 0.161 at 3, 5 and 7 years, respectively. Serum ALT level (>40 IU/l) in the 6th month after commencement of IFN therapy and BMI >25 were associated with shorter time-to-HCC emergence using multivariate analysis (relative risk 16.034, p = 0.01 for ALT >40 IU/l; relative risk 6.020, p = 0.026 for BMI >25, respectively). The IL28B SNP was extracted as a significant factor for the occurrence of HCC.
  
  
  CONCLUSIONS
  Maintenance therapy with the use of long-term low-dose PEG-IFNα-2a is effective for preventing HCC occurrence irrespective of the IL28B SNP, at least for a subset of CHC patients. The initial response of serum ALT levels and BMI provides a prognostic value for determining the risk of developing HCC later in life.
authors.affiliation: Department of Gastroenterology and Hepatology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Hagiwara
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Sakurai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takita
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Minami
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Inoue
authors.forename: Norihisa
authors.initials: N
authors.lastname: Yada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitai
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Nagai
authors.forename: Sousuke
authors.initials: S
authors.lastname: Hayaishi
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arizumi
authors.forename: Naoshi
authors.initials: N
authors.lastname: Nishida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015992:Body Mass Index; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000517:prevention & control / Q000821:virology*; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000235:genetics / Q000517:prevention & control / Q000821:virology*; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D016016:Proportional Hazards Models; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000378:metabolism; D000095022:Interferon Lambda
chemical_list: D000410:Alanine Transaminase; D000998:Antiviral Agents; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D011092:Polyethylene Glycols; D012367:RNA, Viral; D011994:Recombinant Proteins; D000509:alpha-Fetoproteins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C100416:peginterferon alfa-2a